HUMAN GENE THERAPY

metrics 2024

Pioneering Research in Genetic Engineering

Introduction

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.

Metrics 2024

SCIMAGO Journal Rank1.09
Journal Impact Factor3.90
Journal Impact Factor (5 years)5.80
H-Index159
Journal IF Without Self3.90
Eigen Factor0.01
Normal Eigen Factor1.44
Influence1.91
Immediacy Index1.20
Cited Half Life8.60
Citing Half Life6.50
JCI1.00
Total Documents3565
WOS Total Citations6486
SCIMAGO Total Citations53435
SCIMAGO SELF Citations3249
Scopus Journal Rank1.09
Cites / Document (2 Years)2.95
Cites / Document (3 Years)3.21
Cites / Document (4 Years)3.27

Metrics History

Rank 2024

Scopus

Genetics in Biochemistry, Genetics and Molecular Biology
Rank #117/347
Percentile 66.28
Quartile Q2
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #78/178
Percentile 56.18
Quartile Q2
Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #188/410
Percentile 54.15
Quartile Q2

IF (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 50/174
Percentile 71.60
Quartile Q2
GENETICS & HEREDITY
Rank 44/191
Percentile 77.20
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 64/189
Percentile 66.40
Quartile Q2

JCI (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 39/174
Percentile 77.59
Quartile Q1
GENETICS & HEREDITY
Rank 46/191
Percentile 75.92
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 47/189
Percentile 75.13
Quartile Q1

Quartile History

Similar Journals

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Elevating the standards of molecular research excellence.
Publisher: SPANDIDOS PUBL LTDISSN: 1107-3756Frequency: 12 issues/year

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Blood Advances

Empowering Researchers in Blood Advances
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

TRENDS IN MOLECULAR MEDICINE

Empowering Science Through Molecular Breakthroughs
Publisher: CELL PRESSISSN: 1471-4914Frequency: 12 issues/year

TRENDS IN MOLECULAR MEDICINE, published by CELL PRESS, is a premier journal that stands at the forefront of the rapidly evolving fields of molecular biology and molecular medicine. With a distinguished Q1 ranking in both categories and an impressive Scopus standing—ranked #12 out of 410 in Molecular Biology and #6 out of 178 in Molecular Medicine—this journal is a vital source of high-impact research and insights for researchers, professionals, and students alike. The journal, which has been published consistently since 2000, promotes the dissemination of groundbreaking discoveries that bridge the gap between molecular biology and therapeutic applications. Furthermore, TRENDS IN MOLECULAR MEDICINE embraces modern accessibility options, engaging a global audience eager to explore pioneering advancements in human health. Set against the backdrop of the United Kingdom, this esteemed publication not only informs but also inspires ongoing research and innovation in molecular sciences, making it an essential resource for those shaping the future of medicine.

CANCER GENE THERAPY

Driving Progress in Molecular Biology for Cancer Solutions
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

INTERNATIONAL JOURNAL OF HUMAN GENETICS

Unveiling Insights in Molecular Biology
Publisher: KAMLA-RAJ ENTERPRISESISSN: 0972-3757Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

TRENDS IN GENETICS

Fostering Excellence in Genetic Research and Innovation
Publisher: CELL PRESSISSN: 0168-9525Frequency: 12 issues/year

TRENDS IN GENETICS, published by CELL PRESS, is a leading journal in the field of genetics, recognized for its significant impact on research and advancements in the discipline. With an impressive Scopus ranking of #10 out of 347 in the category of Genetics and a 97th percentile ranking, this journal stands as a premier platform for publishing innovative, high-quality articles that shape the future of genetic research. Since its inception in 1985, TRENDS IN GENETICS has been at the forefront of the genetic sciences, continuously disseminating crucial findings while maintaining a strong commitment to scientific rigor and integrity. Although it does not currently offer open access options, its rigorous peer-review process ensures that only the most relevant and groundbreaking studies make it to publication. Scholars and practitioners in genetics will find this journal to be an invaluable resource for keeping abreast of the latest developments, trends, and methodologies that drive the field forward.

FUNCTIONAL & INTEGRATIVE GENOMICS

Advancing the Frontiers of Genomic Understanding
Publisher: SPRINGER HEIDELBERGISSN: 1438-793XFrequency: 4 issues/year

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

GENE THERAPY

Empowering Researchers with Cutting-Edge Discoveries
Publisher: SPRINGERNATUREISSN: 0969-7128Frequency: 12 issues/year

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

CYTOTHERAPY

Elevating Research in Cell Therapy and Transplantation.
Publisher: ELSEVIER SCI LTDISSN: 1465-3249Frequency: 12 issues/year

CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.

Oncology Research and Treatment

Advancing cancer care through innovative research.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.